[
    [
        {
            "time": "2023-04-15",
            "original_text": "Novartis Stock Dives Alongside Pharma Peers Despite First-Quarter Beat",
            "features": {
                "keywords": [
                    "Novartis",
                    "Stock",
                    "Dives",
                    "Pharma",
                    "Peers",
                    "First-Quarter",
                    "Beat"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 8,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-04-15",
            "original_text": "Novartis (NVS) Q1 Earnings and Revenues Surpass Estimates",
            "features": {
                "keywords": [
                    "Novartis",
                    "Q1",
                    "Earnings",
                    "Revenues",
                    "Surpass",
                    "Estimates"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-04-15",
            "original_text": "Biotech Heavyweight Amgen Enters The Coronavirus Arena â€” But Is It A Buy?",
            "features": {
                "keywords": [
                    "Biotech",
                    "Heavyweight",
                    "Amgen",
                    "Coronavirus",
                    "Arena",
                    "Buy"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-04-15",
            "original_text": "The Zacks Analyst Blog Highlights: Intel, Novartis, Toyota Motor, Union Pacific and Biogen",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst",
                    "Blog",
                    "Highlights",
                    "Intel",
                    "Novartis",
                    "Toyota",
                    "Motor",
                    "Union",
                    "Pacific",
                    "Biogen"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "pharmaceuticals",
                    "automobiles",
                    "transportation",
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-04-15",
            "original_text": "Novartis Earnings Beat First-Quarter Views, Guidance Reaffirmed",
            "features": {
                "keywords": [
                    "Novartis",
                    "Earnings",
                    "Beat",
                    "First-Quarter",
                    "Views",
                    "Guidance",
                    "Reaffirmed"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-04-15",
            "original_text": "Novartis CEO: We Feel We Can Maintain Full Year Guidance",
            "features": {
                "keywords": [
                    "Novartis",
                    "CEO",
                    "Maintain",
                    "Full",
                    "Year",
                    "Guidance"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-04-15",
            "original_text": "Novartis sales, profits rise in first quarter on COVID-19 buying rush",
            "features": {
                "keywords": [
                    "Novartis",
                    "sales",
                    "profits",
                    "rise",
                    "first",
                    "quarter",
                    "COVID-19",
                    "buying",
                    "rush"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-04-15",
            "original_text": "Novartis posts first-quarter sales, profit beat as COVID-19 spurs prescriptions",
            "features": {
                "keywords": [
                    "Novartis",
                    "posts",
                    "first-quarter",
                    "sales",
                    "profit",
                    "beat",
                    "COVID-19",
                    "spurs",
                    "prescriptions"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]